Irritable bowel syndrome

被引:5
|
作者
Joel A. Sach
Lin Chang
机构
[1] UCLA/CURE Neuroenteric Disease Program,
关键词
Irritable Bowel Syndrome; Main Drug Interaction; Irritable Bowel Syndrome Patient; Loperamide; Tegaserod;
D O I
10.1007/s11938-002-0049-3
中图分类号
学科分类号
摘要
Because treatment of irritable bowel syndrome (IBS) patients can be frustrating to the clinician and patient as well, the physician should strive to gain the patient’s confidence with a concise, appropriate work-up and by offering reassurance and education that IBS is a functional disorder without significant long-term health risks.First-line treatment should be aimed at treating the most bothersome symptom.Tricyclic antidepressants are superior to placebo in reducing abdominal pain scores, as well as improving global symptom severity [1••].Loperamide is superior to placebo in managing IBS-associated diarrhea [2••].Whereas fiber has a role in treating constipation, its value for IBS or, specifically, in the relief of abdominal pain or diarrhea associated with IBS is controversial [2••].Although certain antispasmodics have demonstrated superiority over placebo in managing abdominal pain, none of these agents are available in the United States [3••].Probiotic therapy using Lactobacillus plantarum has demonstrated superiority to placebo in improving pain, regulating bowel habits, and decreasing flatulence [4].As studied in a recent placebo-controlled prospective study, Chinese herbal medicines significantly improved bowel symptom scores and global symptom profile, and reduced IBS-related quality of life impairment [5].Some of the most promising emerging therapies in IBS revolve around targeted pharmacotherapeutic modulation of serotonin receptors (ie, 5-HT3 and 5-HT4 subtypes), which are involved in sensory and motor functions of the gut. Other investigational agents that are also being explored include cholecystokinin antagonists, α2-adrenergic agonists (eg, clonidine), serotonin reuptake inhibitors (eg, citalopram), and neurokinin antagonists [6].IBS is best understood through the biopsychosocial paradigm, and therefore, its effective management requires a comprehensive multidisciplinary approach based on patient education and reassurance, enhanced by diet recommendations and lifestyle modifications, and complemented by pharmacotherapy and psychosocial intervention in more severe cases.
引用
收藏
页码:267 / 278
页数:11
相关论文
共 50 条
  • [41] Current insights into the pathophysiology of irritable bowel syndrome
    Ines Schwetz
    Sylvie Bradesi
    Emeran A. Mayer
    Current Gastroenterology Reports, 2003, 5 (4) : 331 - 336
  • [42] Evaluation of drug treatment in irritable bowel syndrome
    Talley, NJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (04) : 362 - 369
  • [43] Dietary intakes in people with irritable bowel syndrome
    Elizabeth A Williams
    XuiLi Nai
    Bernard M Corfe
    BMC Gastroenterology, 11
  • [44] The role of probiotics in management of irritable bowel syndrome
    Borowiec A.M.
    Fedorak R.N.
    Current Gastroenterology Reports, 2007, 9 (5) : 393 - 400
  • [45] New concepts of irritable bowel syndrome.
    Mertz H.R.
    Current Gastroenterology Reports, 1999, 1 (5) : 433 - 440
  • [46] Irritable bowel syndrome - A syndrome in evolution
    Lacy, BE
    De Lee, R
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (04) : S230 - S242
  • [47] Treatment of irritable bowel syndrome
    Basnayake, Chamara
    AUSTRALIAN PRESCRIBER, 2018, 41 (05) : 145 - 149
  • [48] Probiotics and irritable bowel syndrome
    Dai, Cong
    Zheng, Chang-Qing
    Jiang, Min
    Ma, Xiao-Yu
    Jiang, Li-Juan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (36) : 5973 - 5980
  • [49] Irritable bowel syndrome in children
    Classen, M.
    MONATSSCHRIFT KINDERHEILKUNDE, 2011, 159 (12) : 1206 - +
  • [50] New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments
    Crowell M.D.
    Harris L.
    Jones M.P.
    Chang L.
    Current Gastroenterology Reports, 2005, 7 (4) : 272 - 279